Wolverine Trading
ABUS icon

Wolverine Trading’s Arbutus Biopharma ABUS Stock Holding History

Wolverine Trading’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$111K Buy
24,800
+1,800
+8% +$6.61K ﹤0.01% 5170
2025
Q2 		$72K Sell
23,000
-200
-0.9% -$664 ﹤0.01% 4251
2025
Q1 		$81.2K Buy
23,200
+10,700
+86% +$35.7K ﹤0.01% 4282
2024
Q4 		$40K Sell
12,500
-8,300
-40% -$30.5K ﹤0.01% 5022
2024
Q3 		$79.7K Buy
+20,800
New +$79.8K ﹤0.01% 4416
2023
Q3 		– Sell
-10,400
Closed -$23.3K – 4401
2023
Q2 		$23.3K Hold
10,400
– – ﹤0.01% 4084
2023
Q1 		$31K Sell
10,400
-10,500
-50% -$29.6K ﹤0.01% 3935
2022
Q4 		$49K Sell
20,900
-6,400
-23% -$15.3K ﹤0.01% 3579
2022
Q3 		$54K Sell
27,300
-100
-0.4% -$235 ﹤0.01% 4116
2022
Q2 		$74K Sell
27,400
-43,300
-61% -$111K ﹤0.01% 3937
2022
Q1 		$211K Buy
70,700
+26,000
+58% +$79.6K ﹤0.01% 4351
2021
Q4 		$173K Buy
+44,700
New +$174K ﹤0.01% 4798

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's ABUS Position: Q4 2022 in Review

Wolverine Trading sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 11,032 shares — an estimated $26.4K sold.

Wolverine Trading first reported a position in ABUS in Q4 2021 and held it in 4 quarters. The position peaked at $59K in Q1 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Wolverine Trading reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Wolverine Trading sold 11,032 Arbutus Biopharma shares in Q4 2022, an estimated $26.4K.
  • Wolverine Trading first reported a position in Arbutus Biopharma in Q4 2021 and held it in 4 quarters.
  • Wolverine Trading's Arbutus Biopharma position peaked at $59K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Wolverine Trading's 13F filing for Q4 2022, filed 14 Feb 2023.